SR-3029

• CAT Number: I001756
• CAS Number: 1454585-06-8
• Molecular Formula: C23H19F3N8O
• Molecular Weight: 480.45
• Purity: ≥95%
• Solubility: DMSO ≥ 31 mg/mL
• Storage: Store at -20°C
• IUPAC Name: N-[(4,5-difluoro-1H-benzimidazol-2-yl)methyl]-9-(3-fluorophenyl)-2-morpholin-4-ylpurin-6-amine
• InChI: InChI=1S/C23H19F3N8O/c24-13-2-1-3-14(10-13)34-12-28-20-21(31-23(32-22(20)34)33-6-8-35-9-7-33)27-11-17-29-16-5-4-15(25)18(26)19(16)30-17/h1-5,10,12H,6-9,11H2,(H,29,30)(H,27,31,32)
• InChIKey: CEBMEQPREMCWOL-UHFFFAOYSA-N
• SMILES: C1COCCN1C2=NC(=C3C(=N2)N(C=N3)C4=CC(=CC=C4)F)NCC5=NC6=C(N5)C=CC(=C6F)F

SR-3029（Cat No.:I001756）is a potent and selective inhibitor of casein kinase 1 delta and epsilon (CK1δ/ε), key regulators of circadian rhythms, cellular signaling, and cancer progression. By inhibiting these kinases, SR-3029 disrupts circadian control and alters the regulation of pathways involved in cell proliferation and survival. It has shown promise in preclinical cancer research, particularly in treating tumors with dysregulated CK1δ/ε activity, such as certain leukemias and solid tumors. SR-3029 is valuable for studying the role of CK1δ/ε in circadian biology and for exploring targeted cancer therapies.

Reference

[1]. Mathieu Bibian et al. Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties. Bioorg Med Chem Lett, 2013 Aug 1, 23(15): 4374-4380.

[2]. Laura H. Rosenberg et al. Therapeutic Targeting of Casein Kinase 1δ in Breast Cancer. Sci Transl Med. 2015 Dec 16, 7(318), 318ra202.